Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes | MicrobiomeTrials← Back to trialsNCT07894861
Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-10-31Est. Completion: 2027-06-30
Enrollment target: 75 participants Other microbiome trials you might be interested in
Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, AcuteLeukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029
Recruiting
Trisomy 8 MosaicismTrisomy 8 Associated Autoinflammatory DiseaseMucosal Ulcerations
Background:
Trisomy 8 mosaicism is a genetic disorder that can increase inflammation in the body. Symptoms include feve…
Bethesda, United StatesEst. completion May 1, 2056